Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®

• Status: Completed
• Trial end date: 2008-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to assess the effects with two different inhaled respiratory medications with regards to improvement of lung function, symptoms and morning activities.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Budesonide; Budesonide, Formoterol Fumarate Drug Combination; Fluticasone; Fluticasone Propionate, Salmeterol Xinafoate Drug Combination; Fluticasone-Salmeterol Drug Combination; Formoterol Fumarate; Salmeterol Xinafoate

Criteria

Inclusion Criteria:

• Outpatient, female or male aged ≥40 years, diagnosis of COPD with symptoms for at least 2 years

• FEV1 ≤50% of predicted normal value, pre-bronchodilator, FEV1/VC <70%

• Pre-bronchodilator

Exclusion Criteria:

• Current respiratory tract disorder other than COPD

• History of asthma or rhinitis

• Significant or unstable cardiovascular disorder